#Synbio darling Ginkgo Bioworks $DNA released their 2022 results along with a 10-K filing. We perused all their year-end collateral for insights, starting with a strong increase in Foundry revenues from third parties and falling related party revenues. That’s the good news. The bad news is that downstream value isn’t looking so hot. Royalties declined year over year, while legacy pass-through contract manufacturing increased (why? who knows). As for milestone revenues, the majority in 2021 and 2022 for Ginkgo Bioworks came from a cannabis firm developing a CBD gummy. And get this. They actually had an impairment charge because the value from those payments didn’t match what they received in return. So far, the big win for DNA stock seems to be a CBD gummy. As for the Zymergen acquisition, we look at that too along with the Bayer deal which doesn’t look as hot as advertised. Again, we’re avoiding Ginkgo Bioworks stock until the company proves that useful products are being developed on their platform, something that’s reflected in royalties. Oh, one more thing. We’d like to see cash brought in by Foundry, er, Cell Engineering, increasing over time, not decreasing. The last few slides of this Ginkgo Biworks analysis are shocking. That’s right. Just like pissing on an electric fence. So what are you waiting for? Watch this DNA stock analysis now, like your portfolio returns depend on it.
RESEARCH PIECES USED IN THIS VIDEO:
1. Ginkgo Bioworks: Beware of the Bait and Switch
https://www.nanalyze.com/2023/03/ginkgo-bioworks-bait-switch/
2. Why Ginkgo Bioworks Stock Soared Yesterday
https://www.nanalyze.com/2022/03/ginkgo-bioworks-stock-soared/
3. Ginkgo Bioworks Responds to Short Seller Report
https://www.nanalyze.com/2021/11/ginkgo-bioworks-short-report/
4. Ginkgo Bioworks Stock Just Got a Whole Lot Riskier
https://www.nanalyze.com/2021/10/ginkgo-bioworks-stock-riskier/
CHAPTERS:
Intro
Ginkgo Bioworks revenue disappointment
A basic success model for Ginkgo
Ginkgo Bioworks’ downstream revenues
The CBD deal with Cronos
Ginkgo’s big biopharma bet
The Zymergen acquisition
The Bayer deal
Ginkgo’s 2023 revenue outlook
Analyzing cell engineering revenues
Conclusion
ABOUT US:
This video is brought to you by Nanalyze, a boutique media and research firm founded by finance professionals with decades of experience. We share insights about #DisruptiveTechnology #investments in a language that is future-proof and easy to understand.
Read all the Nanalyze Premium articles you’d like for free! Sign up for a 30-day trial of our monthly subscription with no strings attached: https://www.nanalyze.com/become-a-nanalyze-premium-subscriber/
DISCLAIMER: Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, along with independently researching and verifying, any information contained within our YouTube videos or on our website, whether for the purpose of making an investment or otherwise.
#Ginkgo #GinkgoBioworks $DNA
source
